Liposomal encapsulated anti-cancer drugs

被引：259

作者：

Hofheinz, RD

Gnad-Vogt, SU

Beyer, U

Hochhaus, A

机构：

[1] Heidelberg Univ, Fak Klin Med Mannheim, Med Klin 3, Onkol Zentrum, D-68167 Mannheim, Germany

[2] Medac GMBH, Wedel, Germany

来源：

ANTI-CANCER DRUGS | 2005年 / 16卷 / 07期

关键词：

D O I：

10.1097/01.cad.0000167902.53039.5a

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Among several drug delivery systems, liposomal encapsulated anti-cancer agents represent an advanced and versatile technology. Several formulations of liposomal anthracyclines are approved, e.g. for the treatment of metastatic breast cancer (pegylated and non-pegylated liposomal doxorubicin) or AIDS-related Kaposi's sarcoma (pegylated liposomal doxorubicin and liposomal daunorubicin). Meanwhile, virtually all anti-cancer drugs have been encapsulated in liposomes using different technologies. This review will summarize preclinical and clinical data of approved and exemplary emerging liposomal anticancer agents.

引用

页码：691 / 707

页数：17

共 127 条

[11]

Boulikas T, 2004, ONCOL REP, V12, P3

[12]

Boulikas T, 2003, ONCOL REP, V10, P1663

[13]

CHAN S, 2001, EUR J CANC S5, V37

[14]

CHIA SK, 2004, P AN M AM SOC CLIN, V23, P630

[15]

CHIEN PY, 2003, P AM ASSOC CANC RES, V44, P1607

[16] Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: A trial of the National Cancer Institute of Canada Clinical Trials Group [J].

Dark, GG ;

Calvert, AH ;

Grimshaw, R ;

Poole, C ;

Swenerton, K ;

Kaye, S ;

Coleman, R ;

Jayson, G ;

Le, T ;

Ellard, S ;

Trudeau, M ;

Vasey, P ;

Hamilton, M ;

Cameron, T ;

Barrett, E ;

Walsh, W ;

McIntosh, L ;

Eisenhauer, EA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1859-1866

[17] Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice [J].

Desjardins, JP ;

Abbott, EA ;

Emerson, DL ;

Tomkinson, BE ;

Leray, JD ;

Brown, EN ;

Hamilton, M ;

Dihel, L ;

Ptaszynski, M ;

Bendele, RA ;

Richardson, FC .

ANTI-CANCER DRUGS, 2001, 12 (03) :235-245

[18]

Devarajan P, 2004, ANTICANCER RES, V24, P2193

[19]

DRAGOVICH T, 2004, P AM SOC CLIN ONCOL, V260

[20]

Drummond DC, 1999, PHARMACOL REV, V51, P691

← 1 2 3 4 5 6 7 8 9 10 →